Constipation-predominant Irritable Bowel Syndrome

Gastroenterology
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
LubiprostoneN/A1 trial
Active Trials
NCT01085643Completed4Est. Dec 2010
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
NeomycinN/A1 trial
Active Trials
NCT00945334CompletedEst. Jun 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaLubiprostone
Bausch HealthNeomycin

Clinical Trials (2)

Total enrollment: 4 patients across 2 trials

NCT01085643TakedaLubiprostone

Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)

Start: Mar 2010Est. completion: Dec 20104 patients
N/ACompleted

Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome

Start: Aug 2009Est. completion: Jun 2013
N/ACompleted

Related Jobs in Gastroenterology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space